Cardiff Oncology (CRDF) AI Stock Analysis

• Market Cap: $206.23M
• Dividend Yield: N/A
• Average Volume (3M): 1.13M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: -3.61%
• EPS Growth: -3.39%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 66,525,856
• 10 Day Avg. Volume: 1,494,032
• 30 Day Avg. Volume: 1,128,683
• PEG Ratio: <0.01
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: 0.23
• Enterprise Value/Revenue: 18.05
• Enterprise Value/Gross Profit: 122.50
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: $11.38
• Price Target Upside: 260.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 50 Neutral
• Price Target: $3.00 ▼(-5.06%Downside)

Cardiff Oncology's stock score is primarily influenced by its significant financial challenges, which weigh heavily despite a strong balance sheet. Technical indicators provide mixed signals, and the lack of positive valuation metrics further impacts the score. However, recent corporate events, including leadership changes and upcoming trial data, offer potential positives.

Positive Factors

Clinical Data

Positive data from the Phase II CRDF-004 study should rerate the stock and propel Onvansertib to pivotal.

Leadership

The company named a new chief medical officer, Dr. Roger Sidhu, who has significant experience in the oncology field, potentially benefiting Cardiff as it evolves into a pivotal-stage biotech company.

Market Position

Cardiff has emerged as one of the highest-conviction ideas in the coverage universe following the initial CRDF-004 data.

Negative Factors

Corporate Changes

Following the two corporate developments, Cardiff shares are expected to pull back due to the Phase II timing delay and the chief medical officer change.

Trial Delays

The ongoing Phase II CRDF-004 trial will now read out later than initially expected, which might concern investors.

Cardiff Oncology Business Overview & Revenue Model

Company Description

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

How the Company Makes Money

Cardiff Oncology makes money through a combination of funding sources typical of clinical-stage biotech companies, such as equity financing, grants, and strategic partnerships. As a company focused on drug development, Cardiff Oncology does not yet generate revenue from product sales. Instead, it relies on raising capital through public and private offerings of its stock to fund its research and development activities. Additionally, the company may receive milestone payments or licensing fees from collaborations with larger pharmaceutical companies interested in its drug candidates. These partnerships can provide crucial financial support and resources needed to advance their clinical trials and bring their products closer to commercialization.

Cardiff Oncology Financial Statement Overview

Summary

Cardiff Oncology is facing significant financial challenges, with declining revenues and persistent losses impacting both profitability and cash flow. Despite a solid balance sheet with low leverage, the company's reliance on external financing and inability to generate sustainable cash flow are major concerns.

Income Statement

The company has been experiencing declining revenue over the recent periods, with a TTM revenue of $588,000 compared to $683,000 in the previous year. Gross profit margin for TTM is 65.8%, indicating decent cost management relative to revenue. However, significant net losses are a concern, with a net profit margin of -8309.18% for TTM, reflecting high operational inefficiencies. The EBIT and EBITDA margins are deeply negative, indicating ongoing operational challenges.

Balance Sheet

The balance sheet reveals a strong equity position with a debt-to-equity ratio of 0.02, suggesting minimal leverage. The equity ratio stands at 83.5% for TTM, indicating a solid financial foundation with most assets financed by equity. However, the company's consistent net losses are eroding equity, which could present long-term risks.

Cash Flow

Operating cash flow remains negative at -$42.7 million for TTM, indicating cash outflows in core operations. The company is heavily reliant on financing activities to sustain operations, as evidenced by a substantial cash inflow from financing. The free cash flow is also negative, aligning with the operational losses, which raises concerns about sustainable cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	588.00K	683.00K	488.00K	386.00K	359.00K	365.99K
Gross Profit	387.00K	279.00K	488.00K	186.00K	-141.00K	-10.87M
EBITDA	-51.57M	-48.25M	-45.01M	-39.67M	-28.40M	-18.84M
Net Income	-48.85M	-45.43M	-41.44M	-37.51M	-27.74M	-19.28M
Balance Sheet
Total Assets	84.81M	97.19M	81.64M	116.19M	149.54M	134.73M
Cash, Cash Equivalents and Short-Term Investments	79.89M	91.75M	74.82M	105.27M	140.82M	130.98M
Total Debt	1.36M	1.52M	2.15M	2.71M	3.12M	869.50K
Total Liabilities	13.93M	14.24M	11.90M	9.85M	9.13M	6.57M
Stockholders Equity	70.88M	82.95M	69.74M	106.34M	140.42M	128.16M
Cash Flow
Free Cash Flow	-42.75M	-37.77M	-31.47M	-34.71M	-23.25M	-16.53M
Operating Cash Flow	-42.75M	-37.69M	-30.89M	-33.82M	-23.04M	-16.31M
Investing Cash Flow	-5.49M	13.73M	36.20M	38.15M	-131.45M	-211.88K
Financing Cash Flow	53.68M	53.78M	0.00	75.00K	35.45M	137.31M

Cardiff Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.16
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRDF, the sentiment is Negative. The current price of 3.16 is below the 20-day moving average (MA) of 3.53, above the 50-day MA of 3.11, and below the 200-day MA of 3.31, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.07 is Neutral, neither overbought nor oversold. The STOCH value of 16.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRDF.

Cardiff Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.41B	0.32	-61.11%	2.34%	16.99%	1.69%
CRDF	50 Neutral	$206.23M	―	-74.15%	―	-3.61%	-3.39%
THRD	49 Neutral	$244.59M	―	-19.94%	―	―	-14.76%
DSGN	47 Neutral	$224.24M	―	-22.59%	―	―	26.63%
IPHA	45 Neutral	$166.69M	―	-160.99%	―	-75.67%	-552.37%
ANNX	38 Underperform	$262.22M	―	-66.13%	―	―	43.21%
NGNE	34 Underperform	$240.74M	―	-34.97%	―	―	-140.77%

Cardiff Oncology Corporate Events

Cardiff Oncology Holds Annual Stockholders Meeting 2025

On June 26, 2025, Cardiff Oncology, Inc. held its Annual Meeting of Stockholders where 38,649,891 shares of common stock were represented. During the meeting, all seven nominees for director were elected to serve until the 2026 Annual Meeting. Additionally, the stockholders ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm, approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares issuable, and endorsed the compensation of the company’s named executive officers.

The most recent analyst rating on (CRDF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.

Cardiff Oncology Appoints New Chief Medical Officer

On June 17, 2025, Cardiff Oncology announced the appointment of Dr. Roger Sidhu as Chief Medical Officer, succeeding Dr. Fairooz Kabbinavar, who will remain in an advisory role. Dr. Sidhu brings over 20 years of oncology leadership experience, having previously held significant roles at Treadwell Therapeutics, Amgen, and Roivant Sciences. The company also plans to release additional clinical data from its CRDF-004 trial on July 29, 2025, which evaluates onvansertib in combination with standard care for first-line RAS-mutated mCRC. This appointment and upcoming data release are expected to advance Cardiff Oncology’s clinical development and potentially impact its market positioning.

The most recent analyst rating on (CRDF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.